The world's first biotechnology company
Bob Swanson, a young associate dismissed from Kleiner Perkins, became captivated by recombinant DNA technology. He cold-called Herbert Boyer, co-inventor of the technology, to explore its commercial potential. The two met, bonded over Swanson's enthusiasm and Boyer's scientific prowess, and decided to establish Genentech. Each contributed $500 to cover legal fees, formalizing their partnership.
Swanson pitched the idea to Tom Perkins at Kleiner Perkins, seeking funding to create synthetic insulin. Perkins proposed a “virtual company” model to minimize risk and costs: contracting work to existing labs instead of building one. This strategy defined Genentech as a lean and focused startup.
Kleiner Perkins invested $100,000 for a 25% stake in Genentech, with a goal of tackling "white-hot risks" incrementally. This stage-by-stage financing method ensured capital efficiency while motivating researchers to hit milestones.
Genentech used contracted laboratories to progress. The University of California, San Francisco, handled gene-splicing tasks, while City of Hope hospital synthesized genes. These collaborations allowed Genentech to achieve groundbreaking results efficiently. By 1978, Genentech announced the successful production of synthetic insulin, a moment that stunned the scientific and business communities.
Perkins's leadership brought a mix of pressure and inspiration. He introduced stock options to incentivize employees and fostered a culture of ownership. His flamboyant persona, complete with a Ferrari and grand gestures, motivated the team while cementing Genentech’s identity as a high-stakes, groundbreaking venture.
Genentech went public on October 14, 1980, with its stock doubling in minutes from the offering price of $35 to $89—a record-breaking IPO. Despite being barely profitable, the company captured investor imagination with its revolutionary technology. The IPO validated Genentech’s model and demonstrated the commercial viability of biotechnology.
In 2009, Genentech became a member of the Roche Group through a landmark acquisition. Roche, a Swiss multinational healthcare company, purchased the outstanding shares of Genentech for $46.8 billion, cementing its control over the biotech pioneer. Despite the merger, Genentech retained its research and early development operations as an independent center within Roche. This structure allowed the company to preserve its entrepreneurial culture and scientific autonomy while benefiting from Roche’s extensive global network and resources.
Headquartered in South San Francisco, California, Genentech remains a biotechnology powerhouse. It has consistently pursued groundbreaking research to treat serious and life-threatening diseases. Among its transformative achievements are the development of the first targeted antibody for cancer and a pioneering medicine for primary progressive multiple sclerosis.
As of 2021, Genentech employs over 13,000 people and continues to innovate across its diverse pipeline of medicines. Its commitment to diversity, inclusion, and fostering a dynamic work environment has earned widespread recognition. Forbes and the Human Rights Campaign have lauded Genentech for its workplace policies and culture.
From its pioneering days of recombinant DNA technology to its position as a key player within Roche, Genentech exemplifies the power of science-driven innovation. Its founding principle—to use cutting-edge science to improve human health—continues to guide its work. As Genentech looks to the future, it remains steadfast in its mission to tackle the world's most pressing medical challenges and improve patient outcomes.
Highlights of Genentech’s Achievements:
Scientific Milestones :
1977: First use of recombinant DNA technology to produce somatostatin.
1978: First production of synthetic insulin.
First targeted antibody for cancer treatment.
First medicine for primary progressive multiple sclerosis.
Pioneering IPO :
First biotechnology company to go public, setting a benchmark for the industry.
Acquisition by Roche :
Preserved independence while leveraging global resources.
Global Impact :
Continuous delivery of life-changing medicines to patients worldwide.
Genentech’s legacy is a testament to the transformative potential of biotechnology and the enduring influence of visionary founders, scientists, and venture capitalists. It remains a shining example of innovation in both science and business.
